DoD Awards $17.4M for Stability Testing to Dynport Vaccine Company LLC
Contract Overview
Contract Amount: $17,415,643 ($17.4M)
Contractor: Dynport Vaccine Company LLC
Awarding Agency: Department of Defense
Start Date: 2021-08-06
End Date: 2026-08-15
Contract Duration: 1,835 days
Daily Burn Rate: $9.5K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 1
Pricing Type: FIRM FIXED PRICE
Sector: R&D
Official Description: STABILITY TESTING
Place of Performance
Location: FREDERICK, FREDERICK County, MARYLAND, 21702
State: Maryland Government Spending
Plain-Language Summary
Department of Defense obligated $17.4 million to DYNPORT VACCINE COMPANY LLC for work described as: STABILITY TESTING Key points: 1. Contract awarded to Dynport Vaccine Company LLC for stability testing. 2. The contract falls under the Research and Development sector, specifically NAICS 541715. 3. Full and open competition was utilized, suggesting a competitive bidding process. 4. The award value is $17.4 million with an estimated completion date in August 2026.
Value Assessment
Rating: fair
The contract value of $17.4 million for stability testing appears reasonable given the 4-year duration. Benchmarking against similar R&D contracts is difficult without more specific service details.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, indicating multiple vendors had the opportunity to bid. This method generally promotes price discovery and competitive pricing.
Taxpayer Impact: Taxpayer funds are being used for critical R&D, with competition aiming to ensure value for money.
Public Impact
Supports Department of Defense research and development initiatives. Potential for advancements in vaccine stability and efficacy. Contract duration of 4 years allows for comprehensive testing and analysis.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Lack of specific performance metrics for stability testing.
- Potential for cost overruns in long-term R&D projects.
Positive Signals
- Awarded through full and open competition.
- Clear contract duration and award value.
Sector Analysis
This contract falls within the R&D sector, specifically focusing on physical, engineering, and life sciences. Spending in this area is crucial for technological advancement but can be subject to long development cycles and uncertain outcomes.
Small Business Impact
The data does not indicate whether small businesses were involved as subcontractors or prime contractors in this award.
Oversight & Accountability
Oversight will be crucial to ensure the stability testing meets DoD requirements and that funds are used efficiently throughout the contract's duration.
Related Government Programs
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Department of Defense Contracting
- Department of the Army Programs
Risk Flags
- Potential for scope creep in R&D projects.
- Reliance on a single vendor for critical testing.
- Uncertainty of research outcomes.
- Long contract duration may lead to evolving requirements.
Tags
research-and-development-in-the-physical, department-of-defense, md, definitive-contract, 10m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Defense awarded $17.4 million to DYNPORT VACCINE COMPANY LLC. STABILITY TESTING
Who is the contractor on this award?
The obligated recipient is DYNPORT VACCINE COMPANY LLC.
Which agency awarded this contract?
Awarding agency: Department of Defense (Department of the Army).
What is the total obligated amount?
The obligated amount is $17.4 million.
What is the period of performance?
Start: 2021-08-06. End: 2026-08-15.
What specific stability testing protocols will be employed, and how do they align with industry best practices to ensure the integrity of the research?
The specific stability testing protocols are not detailed in the provided data. However, for R&D contracts of this nature, it is expected that the Department of Defense would require adherence to established scientific methodologies and potentially Good Laboratory Practices (GLP). The effectiveness of the testing hinges on the rigor and appropriateness of these protocols in assessing vaccine stability under various conditions.
What are the key performance indicators (KPIs) for this contract, and how will the government measure the success of the stability testing beyond just completion?
Key performance indicators are not explicitly stated in the provided data. Success in stability testing is typically measured by the achievement of predefined stability endpoints, adherence to timelines, and the quality and reproducibility of the data generated. The government will likely assess the contractor's ability to meet these scientific and contractual milestones.
Given the $17.4 million award and 4-year duration, what is the projected cost per unit of testing, and how does this compare to industry benchmarks for similar R&D services?
A precise per-unit cost is not calculable without knowing the total number of units to be tested. However, the total award value of $17.4 million over approximately 4 years suggests a significant investment in R&D. Benchmarking is challenging without more granular data on the scope and complexity of the stability testing required.
Industry Classification
NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Product/Service Code: RESEARCH AND DEVELOPMENT › C – National Defense R&D Services
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Solicitation ID: W911QY21R0021
Offers Received: 1
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Parent Company: Wico Limited
Address: 110 THOMAS JOHNSON DR, FREDERICK, MD, 21702
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Limited Liability Corporation, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $29,135,827
Exercised Options: $17,415,643
Current Obligation: $17,415,643
Actual Outlays: $309,058
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Cost or Pricing Data: NO
Timeline
Start Date: 2021-08-06
Current End Date: 2026-08-15
Potential End Date: 2027-12-15 00:00:00
Last Modified: 2025-12-04
More Contracts from Dynport Vaccine Company LLC
- 199802!2100!1273!MD17 !US Army Medical Research ACQ Act!damd1798c8024 !A!*!* !19971106!19971130!958462681!927921627!003242013!n!03543!dyntel Corp !2000 Edmund Halley DR !reston !va!20191!66672!059!51!reston !fairfax !virginia !0001!+000019021453!n!n!000000000000!an13!rdte/Biomedical - ADV Tech DEV !c9b!medical & Dental Supplies & Eq!1000!not Discernable or Classified !2836!3!*!*!*!B!B!*!A !U!R!2!004!C!* !C!N!Z!* !* !n!c!*!a!z!a!a!a!*!* !*!n!a!c!n!*!*!*!*!*! — $803.3M (Department of Defense)
- Federal Contract — $235.1M (Department of Health and Human Services)
- Program Reporting - Technical — $117.6M (Department of Defense)
- Jalaremia Vaccine Development Team — $31.8M (Department of Health and Human Services)
- - Research&development in Support of the US Army Medical Materiel Development Activity (usammda) for the Performance of a Phase I, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Long-Term Ophthalmic Safety of Tafenoquine Versus Placebo — $24.2M (Department of Defense)
Other Department of Defense Contracts
- Federal Contract — $51.3B (Humana Government Business Inc)
- Lrip LOT 12 Advance Acquisition Contract — $35.1B (Lockheed Martin Corporation)
- SSN 802 and 803 Long Lead Time Material — $34.7B (Electric Boat Corporation)
- 200204!008532!1700!AF600 !naval AIR Systems Command !N0001902C3002 !A!N! !N! !20011026!20120430!008016958!008016958!834951691!n!lockheed Martin Corporation !lockheed Blvd !fort Worth !tx!76108!27000!439!48!fort Worth !tarrant !texas !+000026000000!n!n!018981928201!ac15!rdte/Aircraft-Eng/Manuf Develop !a1a!airframes and Spares !2ama!jast/Jsf !336411!E! !3! ! ! ! ! !99990909!B! ! !A! !a!n!r!2!002!n!1a!a!n!z! ! !N!C!N! ! ! !a!a!a!a!000!a!c!n! ! ! !Y! !N00019!0001! — $34.2B (Lockheed Martin Corporation)
- KC-X Modernization Program — $32.0B (THE Boeing Company)